Brokerage Firm Rating on Seattle Genetics (SGEN)

Seattle Genetics (SGEN) has an average broker rating of 2.1, which is interpreted as a Buy, as rated by 10 equity analysts. Nonetheless, 4 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 5 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Seattle Genetics (SGEN) : 9 investment research analysts covering Seattle Genetics (SGEN) have an average price target of $55.78 for the near short term. The highest target price given by the Brokerage Firm to the stock is $130 and the lowest target is $33 for the short term. Analysts expect the variance to be within $29.56 of the average price.


Company shares have received an average consensus rating of Hold for the current week Seattle Genetics (NASDAQ:SGEN): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $46.17 and $45.30 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $46.62. The buying momentum continued till the end and the stock did not give up its gains. It closed at $46.50, notching a gain of 1.62% for the day. The total traded volume was 393,696 . The stock had closed at $45.76 on the previous day.

In a related news, Siegall Clay B, director officer (President and CEO) of Seattle Genetics Inc /Wa, unloaded 4,042 shares at an average price of $45.21 on July 27, 2016. The total amount of the transaction was worth $182,739, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Companys marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology. In addition to ADCETRIS, the Companys pipeline includes six clinical-stage ADC programs consisting of SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. In addition, it has multiple preclinical and research-stage programs that employ its technologies. Its technologies include ADC technology and Seattle Genetics sugar-engineered antibody (SEA) technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *